By applying innovative medicinal chemistry and its unique protein conformation detection technology, Quanta aims to advance two differentiated, next-generation RAS programs that address the resistance paradigms of targeted therapy in oncology.

Source: https://forextv.com/top-news/quanta-therapeutics-announces-two-late-breaking-preclinical-presentations-from-kras-inhibitor-pipeline-at-annual-aacr-meeting/